


This article was downloaded by: [RMIT University]

On: 04 September 2013, At: 01:12

Publisher: Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides and Nucleotides

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/Incn19>

Synthesis of Certain Acyclic Nucleoside Analogs of 1,2,4-Triazolo[3,4-f][1,2,4]triazine and Pyrimido[5,4-d]pyrimidine

T. Sudhakar Rao ^a & Ganapathi R. Revankar ^a

^a Triplex Pharmaceutical Corporation, 9391 Grogans Mill Road, The Woodlands, TX, 77380

Published online: 24 Sep 2006.

To cite this article: T. Sudhakar Rao & Ganapathi R. Revankar (1995) Synthesis of Certain Acyclic Nucleoside Analogs of 1,2,4-Triazolo[3,4-f][1,2,4]triazine and Pyrimido[5,4-d]pyrimidine, *Nucleosides and Nucleotides*, 14:7, 1601-1612

To link to this article: <http://dx.doi.org/10.1080/15257779508009495>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>


SYNTHESIS OF CERTAIN ACYCLIC NUCLEOSIDE ANALOGS OF 1,2,4-TRIAZOLO[3,4-*f*][1,2,4]TRIAZINE AND PYRIMIDO[5,4-*d*]PYRIMIDINE

T. Sudhakar Rao* and Ganapathi R. Revankar

Triplex Pharmaceutical Corporation, 9391 Grogans Mill Road,
The Woodlands, TX 77380


Abstract: Synthesis of 2-penten-1-yl (**8a**) and ganciclovir analog (**8b**) of 1,2,4-triazolo[3,4-*f*][1,2,4]triazine was accomplished by the ring annulation of the corresponding hydrazides (**6a** and **6b**), which in turn was obtained by the dehydrative coupling of **4** with **5a** or **5b**. Base catalysed ring expansion of N9-alkylpurine-6-carbonitriles (**10a**, **10c**, **10e**) provided the acyclic analogs of 4-aminopyrimido[5,4-*d*]pyrimidines (**13a**, **13d**, **13e**). Debenzylation of **13e** afforded the ganciclovir analog (**13f**) of 4-amino-8-(β -D-ribofuranosylamino)-pyrimido[5,4-*d*]pyrimidine. However, compound **10b** did not undergo the expected rearrangement but resulted in the formation of the methyl formimidate derivative (**12**).

Recently there has been considerable interest in the synthesis of acyclic purine nucleoside analogs¹, mainly due to the observation that 9-[(2-hydroxyethoxy)methyl]guanine (acyclovir) is a selective antiherpes agent², and is the drug of choice in the treatment of diseases caused by herpes simplex virus type-1 (HSV-1). 9-(4-Hydroxybutyl)guanine (HBG), a carba analog of acyclovir, is also found to inhibit HSV-1 in animals³. 9-[(1,3-Dihydroxy-2-propoxy)-methyl]guanine (ganciclovir, DHPG), another acyclic guanosine analog, is the current drug of choice for human cytomegalovirus (HCMV) infections⁴.



Recently, we reported the synthesis and the antiviral properties of 2-penten-1-yl (1) and 3-methyl-2-buten-1-yl derivatives of 5-aminothiazolo[4,5-d]pyrimidine-2,7-dione^{5,6}. Compound 1 was shown to be approximately 10 fold more active *in vitro* against HCMV than DHPG in similar experiments⁵. In continuation of these studies on the synthesis of acyclic nucleoside analogs⁵⁻⁸, we now report the synthesis of certain acyclic nucleoside analogs of 1,2,4-triazolo[3,4-f][1,2,4]triazine and pyrimido[5,4-d]pyrimidine. The synthesis of these acyclic nucleoside analogs is of particular interest, since the ribofuranosyl derivative 6-amino-3-β-D-ribofuranosyl-1,2,4-triazolo[3,4-f][1,2,4]triazin-8(7H)-one (2) exhibited interesting biological properties⁹. Similarly, 4-amino-8-(β-D-ribofuranosylamino)pyrimido[5,4-d]pyrimidine (ARPP, 3) was found to possess significant activity against a variety of DNA and RNA viruses¹⁰⁻¹³.


The synthesis of 2-pentenyl derivative (8a) and ganciclovir analog (8b) of 1,2,4-triazolo[3,4-f][1,2,4]triazine was accomplished starting from 3-amino-6-hydrazino-1,2,4-triazin-5(4H)-one¹⁴ (4) and the corresponding carboxylic acids (5a and 5b, Scheme 1). Thus, dehydrative coupling of 4 with 2-hexenoic acid (5a) in dry DMF in the presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) gave the viable intermediate 6a, which on heating in ethylene glycol at 200 °C afforded the ring cyclized product 6-amino-3-(2-penten-1-yl)-1,2,4-triazolo[3,4-f][1,2,4]triazin-8(7H)-one (8a) in a 75.8% yield. Similarly, the synthesis of the ganciclovir congener (8b) was accomplished starting from 4 and 1,3-dibenzyloxy-2-propoxyacetic acid (5b). The acid 5b was prepared by the condensation of the sodium salt of 1,3-dibenzyloxy-2-propanol with ethyl chloroacetate in dry CH₃CN, followed by alkaline hydrolysis of the intermediate ester. The dehydrative coupling of 4 with 5b in dry DMF afforded the hydrazide 6b in good yield. The ring annulation of 6b was accomplished by



Scheme 1

heating in ethylene glycol at 200 °C for 2 h and the ring closed product 7 was isolated in 58% yield. Removal of the protecting groups of 7 was carried out by reductive debenzoylation by the treatment with Pd(OH)₂/C in absolute EtOH in the presence of cyclohexene. The desired product 6-amino-3-[(1,3-dihydroxy-2-propoxy)methyl]-1,2,4-triazolo[3,4-*f*][1,2,4]triazin-8(7*H*)-one (8b) was obtained in 74% yield.

The synthesis of the acyclic derivatives of pyrimido[5,4-*d*]pyrimidine was achieved by utilizing the base catalysed rearrangement^{15,16} of 9-substituted-purine-6-carbonitriles. The required intermediates for the ring transformation reaction were prepared by direct alkylation of the sodium salt of purine-6-carbonitrile¹⁷ (9), generated *in situ* by the treatment with NaH, with the appropriate alkyl halide. Thus, alkylation of the sodium salt of 9 either with 1-bromo-2-pentene or 4-bromo-2-methyl-2-butene in dry CH₃CN afforded the N-9 and N-7 alkylated products (10a, 10b, and 11a, 11b) (Scheme 2). However, in



Scheme 2

both the cases N-9 isomer was found to be the major component. The positional isomers **10a** and **11a** were separated into the pure components by silica gel column chromatography and were isolated in 56% and 11% yields, respectively. Similarly, 3-methyl-2-butenyl derivatives **10b** and **11b** were isolated in 59% and 17% yields, respectively. The structural assignment of the N-9 positional isomers **10a** and **10b** was based on the comparison of the uv spectral data to that of the corresponding ribonucleoside¹¹. Treatment of **10a** with large excess of NH_4OH in MeOH gave the rearranged product 4-amino-8-(2-penten-1-ylamino)-pyrimido[5,4-*d*]pyrimidine (**13a**). However, a similar treatment of **10b** with methanolic NH_4OH did not give the rearranged product, but resulted in the formation of methyl 9-(3-methyl-2-buten-1-yl)purine-6-formimidate (**12**). Although the addition of MeOH to a carbonitrile functionality to give the methylformimidate is well documented^{18,19}, the reason for resistance of the imidazole moiety to ring open under the conditions used is not clear at this time.

Alkylation of **9** either with [(2-acetoxyethoxy)methyl] bromide²⁰ or 1,3-dibenzoyloxy-2-chloromethylglycerol²¹ resulted mainly in the formation of N-9 substituted derivatives (**10c**, **10e**). Although the formation of a minor amount of N-7 isomer was detected by TLC procedures, no attempts were made to isolate

these compounds. The N-9 isomeric products **10c** and **10e** were isolated in 84% and 78% yields, respectively. Treatment of **10c** with $\text{NH}_4\text{OH}/\text{MeOH}$ at room temperature for 22 h gave the acyclovir analog 4-amino-8-[(2-hydroxyethoxy)methylamino]pyrimido[5,4-*d*]pyrimidine (**13d**). A similar treatment of **10e** with $\text{NH}_4\text{OH}/\text{MeOH}$ resulted in an intractable reaction mixture from which the desired rearrangement product **13e** was isolated and subsequently subjected to reductive debenzoylation with $\text{Pd}(\text{OH})_2/\text{C}$ in absolute EtOH in the presence of cyclohexene. The product 4-amino-8-[(1,3-dihydroxy-2-propoxy)methylamino]pyrimido[5,4-*d*]pyrimidine (**13f**) was isolated in rather low yield. The compounds **8a**, **8b**, **13a**, **13d** and **13f** were tested against HCMV (strain AD 169) in MRC5 cells using the plaque reduction assay²². None of the compounds tested showed any activity against HCMV.

In summary the synthesis of 2-penten-1-yl derivative and ganciclovir analog of 1,2,4-triazolo[3,4-*f*][1,2,4]triazine and the novel acyclic analogs of ARPP is accomplished in good yields.

EXPERIMENTAL

Melting points (uncorrected) were determined with a Thomas-Hoover capillary melting-point apparatus. Elemental analyses were performed by Quantitative Technologies Inc., Whitehouse, NJ. The presence of solvent as indicated by elemental analysis was verified by ^1H NMR spectroscopy. Thin layer chromatography (TLC) was performed on aluminum plates coated (0.2 mm) with silica gel 60F₂₅₄ (EM Reagents). Silica gel (Whatman; 230-400 mesh) was used for flash column chromatography. All solvents and chemicals used were reagent grade and the solvent mixtures are in volumes. The detection of nucleoside components on TLC was by uv light. Evaporations were conducted under diminished pressure with the bath temperature below 30 °C. Infrared (IR) spectra were recorded in KBr with Perkin-Elmer 1420 IR spectrophotometer and ultraviolet spectra (UV) were recorded with a Hewlett-Packard 8452 diode array spectrophotometer. Mass spectra (MS) were obtained from Baylor College of Medicine, Houston, Texas. Nuclear magnetic resonance (^1H NMR) spectra were recorded in $\text{DMSO}-d_6$ at 400 MHz with a Bruker AM400 wide bore spectrometer. The chemical shift values are expressed in δ values (parts per million) relative to tetramethylsilane as the internal standard (key: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet and br = broad).

6-Amino-3-(2-penten-1-yl)-1,2,4-triazolo[3,4-f][1,2,4]-triazin-8(7H)-one

(8a). To a suspension of 3-amino-6-hydrazino-1,2,4-triazin-5(4H)-one¹⁴ (**4**, 0.71 g, 5 mmol), *trans*-3-hexenoic acid (**5a**, 0.59 mL, 5 mmol) and 1-hydroxybenzotriazole monohydrate (HOBT, 0.67 g, 5 mmol) in dry DMF (30 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC, 0.96 g, 5 mmol). The mixture was stirred at room temperature overnight and the insoluble material was removed by filtration. The solid was washed with MeOH (10 mL) and the combined filtrates was allowed to stand at room temperature overnight. The product that crystallized was collected by filtration and dried to yield 0.5 g (42%) of **6a**, mp 254–256 °C; UV (MeOH): λ_{max} 274 nm (ϵ 4700); ¹H NMR: δ 0.94 (t, 3 H, CH₃), 2.00 (m, 2 H, CH₂CH₃), 2.84 (d, 2 H, CH₂CO), 5.47, 5.55 (2m, 2 H, CH=CH), 6.36 (s, 2 H, NH₂), 7.77 (s, 1 H, NH), 9.52 (s, 1 H, NH), 11.14 (s, 1 H, NH). *Anal.* Calcd. for C₉H₁₄N₆O₂: C, 45.37; H, 5.92; N, 35.28. Found: C, 45.13; H, 5.84; N, 35.14.

A mixture of **6a** (0.3 g, 1.26 mmol) and ethylene glycol (20 mL) was heated at 200 °C (bath temperature) for 2 h. The reaction mixture was cooled to room temperature and poured into cold H₂O (100 mL). After stirring for 15 min the precipitated product was collected by filtration. The filtrate was extracted with EtOAc (2 \times 250 mL) and the combined organic phase was washed with saturated NaHCO₃ solution (50 mL). Organic layer was evaporated to give a total yield of 0.21 g (75.8%) of **8a** as a colorless solid, mp > 290 °C; UV (MeOH): λ_{max} 276 nm (ϵ 3600); IR: ν 3190, 3340 (NH, NH₂), 1720 (C=O) cm⁻¹; ¹H NMR: δ 0.94 (t, 3 H, CH₃), 2.01 (m, 2 H, CH₂CH₃), 3.57 (d, 2 H, CCH₂), 5.61 (m, 2 H, CH=CH), 6.32 (s, 2 H, NH₂), 11.40 (brs, 1 H, NH). *Anal.* Calcd. for C₉H₁₂N₆O: C, 49.08; H, 5.49; N, 38.16. Found: C, 49.14; H, 5.43; N, 37.92.

1,3-Dibenzyloxy-2-propoxyacetic acid (5b). To a solution of 1,3-dibenzyloxy-2-propanol (2.72 g, 10 mmol) in anhydrous CH₃CN (25 mL) was added NaH (0.3 g, 10 mmol, 60% dispersion in oil). The mixture was stirred at room temperature for 20 min and ClCH₂COOEt (1.23 g, 10 mmol) was added. The reaction mixture was stirred at room temperature for 20 h and the solvent was evaporated. The residue was partitioned between H₂O and CH₂Cl₂ (150 mL). Dichloromethane layer was separated, dried (Na₂SO₄) and evaporated. The residue was purified by chromatography over a silica gel column (2 \times 25 cm) and the product was eluted with hexane:CH₂Cl₂ (1:1) to hexane:CH₂Cl₂ (1:4) to yield 1.0 g (27.9%) of pure 1,3-dibenzyloxy-2-propoxyethyl acetate. ¹H NMR: δ 1.16 (t,

3 H, CH₃), 3.56 (d, 4 H, 2 OCH₂), 3.80 (m, 1 H, OCH), 4.07 (q, 2 H, CH₂), 4.23 (s, 2 H, CH₂), 4.48 (s, 4 H, 2 CH₂Ph), 7.27-7.34 (m, 10 H, Aryl H).

To a solution of 1,3-dibenzyloxy-2-propoxyethyl acetate (0.8 g, 2.23 mmol) in absolute EtOH (6 mL) was added 1 N NaOH solution (3 mL) and the mixture was heated at 85 °C for 2 h. The reaction mixture was allowed to cool to room temperature and the pH of the solution was adjusted to 4. The aqueous solution was extracted with CH₂Cl₂ (2 × 50 mL) and the combined organic phase was dried (Na₂SO₄). The solvent was evaporated to give 0.65 g (88.2%) of **5** as a colorless oil. ¹H NMR: δ 3.54 (d, 4 H, 2 OCH₂), 3.75 (m, 1 H, OCH), 3.98 (s, 2 H, COCH₂), 4.48 (s, 4 H, 2 CH₂Ph), 7.27-7.36 (m, 10 H, Aryl H). *Anal.* Calcd. for C₁₉H₂₂O₅: C, 69.07; H, 6.71. Found: C, 68.53; H, 6.73.

3-[(1,3-Dibenzyloxy-2-propoxy)methyl]-1,2,4-triazolo[3,4-*f*][1,2,4]triazin-8(7*H*)-one (7). A suspension of **4** (284 mg, 2 mmol) and 1,3-dibenzyloxy-2-propoxyacetic acid (**5b**, 0.66 g, 2 mmol) was co-evaporated with anhydrous DMF (2 × 20 mL). The mixture was suspended in dry DMF (15 mL) to which HOBT (0.27 g, 2 mmol) and EDC (0.38 g, 2 mmol) were added. The mixture was stirred at room temperature for 18 h. DMF was evaporated and the residue was dissolved in a small amount of CH₂Cl₂ (20 mL). The insoluble material was removed by filtration and the solid was washed with CH₂Cl₂ (30 mL). The combined filtrates were evaporated and the residue was purified by chromatography on a silica gel column (2 × 15 cm). The product was eluted with 0-10% MeOH in CH₂Cl₂ to yield 0.68 g (72.26%) of **6b**, mp 84-87 °C; UV (MeOH): λ_{max} 276 nm (ε 6300); ¹H NMR: δ 3.57 (m, 4 H, 2 OCH₂), 3.85 (m, 1 H, OCH), 4.13 (s, 2 H, CH₂), 4.51 (s, 4 H, 2 CH₂Ph), 6.47 (s, 2 H, NH₂), 7.25-7.35 (m, 10 H, Aryl H), 7.95 (d, 1 H, NH), 9.35 (d, 1 H, NH), 11.20 (s, 1 H, NH). *Anal.* Calcd. for C₂₂H₂₆N₆O₅ · 1.5 H₂O: C, 54.87; H, 6.06. Found: C, 54.75; H, 5.72.

A suspension of **6b** (0.39 g, 0.83 mmol) in ethylene glycol (25 mL) was heated at 200 °C for 2 h. The reaction flask was allowed to cool to room temperature and the solution was poured into H₂O (100 mL). The product that precipitated was collected by filtration and dried under vacuum to yield 0.21 g (55.8%) of **7**, mp 175-176 °C; UV (MeOH): λ_{max} 276 nm (ε 3620); ¹H NMR: δ 3.53 (m, 4 H, 2 OCH₂), 3.92 (m, 1 H, OCH), 4.44 (s, 4 H, 2 CH₂Ph), 4.86 (s, 2 H, CH₂), 6.44 (s, 2 H, NH₂), 7.24-7.34 (m, 10 H, Aryl H), 11.56 (s, 1 H, NH). *Anal.* Calcd. for C₂₂H₂₄N₆O₄: C, 60.54; H, 5.54; N, 19.26. Found: C, 60.56; H, 5.48; N, 18.85.

6-Amino-3-[(1,3-dihydroxy-2-propoxy)methyl]-1,2,4-triazolo[3,4-f][1,2,4]-triazin-8(7H)-one (8b). To a suspension of **7** (0.17 g, 0.37 mmol) in absolute EtOH (35 mL) and cyclohexene (8 mL) was added Pd(OH)₂/C (20%, 35 mg) and the mixture was heated under reflux overnight. Water (50 mL) was added and the mixture was refluxed for additional one hour. The hot solution was filtered. The solid was again extracted by boiling with MeOH:H₂O (1:1, 50 mL). The combined filtrates were evaporated to give a colorless solid. The solid was triturated with CH₂Cl₂ (10 mL) and the product was collected by filtration to yield 75 mg (74.2%) of **8b**, mp 240-242 °C; UV (MeOH): λ_{max} 276 nm (ε 3650); IR: ν 3180, 3310, 3380, 3500 (OH, NH, NH₂), 1725 (C=O) cm⁻¹; ¹H NMR: δ 3.49 (m, 5 H, OCH, 2 OCH₂), 4.57 (br s, 2 H, 2 OH), 4.85 (s, 2 H, CH₂), 6.46 (s, 2 H, NH₂); MS (FAB): m/e 257.3 (M+H). Anal. Calcd. for C₈H₁₂N₆O₄: C, 37.50; H, 4.72; N, 32.80. Found: C, 37.32; H, 4.69; N, 31.20.

9-(2-Penten-1-yl)purine-6-carbonitrile (10a) and 7-(2-Penten-1-yl)purine-6-carbonitrile (11a). To a suspension of purine-6-carbonitrile¹⁷ (**9**, 0.72 g, 5 mmol) in dry CH₃CN (80 mL) was added NaH (0.2 g, 5 mmol, 60% dispersion in oil). After stirring the mixture at room temperature for 25 min, 1-bromo-2-pentene (predominantly Z olefin, 0.6 mL, 5 mmol) was added and the stirring was continued for 20 h. The insoluble material was removed by filtration. The filtrate was evaporated and the residue containing a mixture of positional isomers were separated by flash column (2 × 25 cm) chromatography using 0-12% EtOAc in CH₂Cl₂ as the eluent. The initial fractions contained the N-9 isomer and the subsequent fractions contained the N-7 isomer. The fractions were collected separately and evaporated to give the pure isomers **10a** and **11a** as viscous liquids.

9-(2-Penten-1-yl)purine-6-carbonitrile (10a). Yield, 0.6 g (56.28%); UV (MeOH): λ_{max} 290 nm (ε 12,600); ¹H NMR: δ 1.00 (t, 3 H, CH₃), 2.23 (m, 2 H, CH₂CH₃), 5.18 (d, 2 H, NCH₂), 5.67 (m, 2 H, CH=CH), 9.02 (s, 1 H, C₈H), 9.16 (s, 1 H, C₂H). Anal. Calcd. for C₁₁H₁₁N₅·0.1 H₂O: C, 61.43; H, 5.25; N, 32.57. Found: C, 61.36; H, 4.99; N, 32.74.

7-(2-Penten-1-yl)purine-6-carbonitrile (11a). Yield: 0.12 g (11.26%); UV (MeOH): λ_{max} 298 nm (ε 7000); ¹H NMR: δ 1.00 (t, 3 H, CH₃), 2.28 (m, 2 H, CH₂CH₃), 5.00 (d, 2 H, NCH₂), 5.63 (m, 2 H, CH=CH), 8.94 (s, 1 H, C₈H), 9.13 (s, 1 H, C₂H). Anal. Calcd. for C₁₁H₁₁N₅·0.1 H₂O: C, 61.43; H, 5.25; N, 32.57. Found: C, 61.34; H, 5.27; N, 32.73.

4-Amino-8-(2-penten-1-ylamino)pyrimido[5,4-*d*]pyrimidine (13a). To a solution of **10a** (0.5 g, 2.34 mmol) in MeOH (30 mL) was added NH₄OH (70 mL) and the mixture was stirred at room temperature for 22 h. The solvent was evaporated and the residue was purified by chromatography on a silica gel column (2 × 10 cm). The product was eluted with 0-8% MeOH in CH₂Cl₂ to yield 0.26 g (48.2%) of **13a**, mp 185-186 °C; UV (MeOH): λ_{max} 298 nm (ε 18,100), 318 (15,200), 336 (9700); IR: ν 3295, 3460 (NH, NH₂) cm⁻¹; ¹H NMR: δ 0.97 (t, 3 H, CH₃), 2.15 (m, 2 H, CH₂CH₃), 4.13 (t, 2 H, NCH₂, collapsed to a doublet on D₂O exchange), 5.48 (m, 2 H, CH=CH), 7.65, 7.89 (2s, 2 H, NH₂), 8.34 (t, 2 H, C₆H, NH, collapsed to a singlet on D₂O exchange), 8.42 (s, 1 H, C₂H). *Anal.* Calcd. for C₁₁H₁₄N₆·0.25 MeOH: C, 56.70; H, 6.34; N, 35.28. Found: C, 56.88; H, 6.03; N, 35.54.

9-(3-Methyl-2-buten-1-yl)purine-6-carbonitrile (10b) and 7-(3-Methyl-2-buten-1-yl)purine-6-carbonitrile (11b). In a similar manner as described for the preparation of **10a** and **11a**, alkylation of **9** (0.73 g, 5 mmol) in dry CH₃CN (80 mL) containing NaH (60% dispersion in oil, 0.2 g, 5 mmol) with 4-bromo-2-methyl-2-butene (0.75 mL, 6.5 mmol) gave a mixture of positional isomers which were separated by silica gel column (2 × 20 cm) chromatography. The products were eluted with CH₂Cl₂ containing 0-20% EtOAc. The initial fractions contained the pure N-9 isomer and the subsequent fractions contained the pure N-7 isomer.

9-(3-Methyl-2-buten-1-yl)purine-6-carbonitrile (10b). Yield, 0.63 g (59%); mp 64-66 °C; UV (MeOH): λ_{max} 290 nm (ε 11,000); ¹H NMR: δ 1.73, 1.84 (2s, 6 H, 2 CH₃), 4.94 (d, 2 H, NCH₂), 5.45 (m, 1 H, CH), 8.93 (s, 1 H, C₈H), 9.14 (d, 1 H, C₂H). *Anal.* Calcd. for C₁₁H₁₁N₅: C, 61.95; H, 5.20; N, 32.85. Found: C, 61.83; H, 5.09; N, 32.75.

7-(3-Methyl-2-buten-1-yl)purine-6-carbonitrile (11b). Yield, 0.18 g (17%); mp 90-92 °C; UV (MeOH): λ_{max} 298 nm (ε 10,200); ¹H NMR: δ 1.76, 1.81 (2s, 6 H, 2 CH₃), 4.92 (d, 2 H, NCH₂), 5.45 (m, 1 H, CH), 8.77 (s, 1 H, C₈H), 9.03 (d, 1 H, C₂H). *Anal.* Calcd. for C₁₁H₁₁N₅: C, 61.95; H, 5.20; N, 32.85. Found: C, 61.77; H, 5.17; N, 31.97.

Methyl 9-(3-methyl-2-buten-1-yl)purine-6-formimidate (12). To a solution of **10b** (0.35 g, 1.64 mmol) in MeOH (15 mL) was added concd. NH₄OH (25 mL). The mixture was stirred at room temperature for 16 h and allowed to stand

at 0 °C for 4 h. The colorless solid that deposited was collected by filtration and washed with a small amount of cold MeOH. The solid was dried under vacuum to give 0.24 g (59%) of pure **12**, mp 140-42 °C; UV (MeOH): λ_{max} 286 nm (ϵ 12,700); IR: ν 3290 (NH) cm^{-1} ; ^1H NMR: δ 1.72, 1.84 (2s, 6 H, 2 CH_3), 3.93 (s, 3 H, OCH_3), 4.92 (d, 2 H, NCH_2), 5.45 (m, 1 H, CH), 8.77 (s, 1 H, C_8H), 9.03 (d, 1 H, C_2H), 9.85 (s, 1 H, NH). *Anal.* Calcd. for $\text{C}_{12}\text{H}_{15}\text{N}_5\text{O}$: C, 58.76; H, 6.16; N, 28.55. Found: C, 58.69; H, 6.07; N, 28.61.

9[(2-Acetoxyethoxy)methyl]purine-6-carbonitrile (10c). To a solution of **9** (0.72 g, 5 mmol) in dry CH_3CN (75 mL) was added NaH (0.2 g, 5 mmol, 60% dispersion in oil). After stirring the mixture at room temperature for 30 min, [(2-acetoxyethoxy)methyl] bromide²⁰ (1.28 g, 6.5 mmol) was added and the reaction was continued overnight. The insoluble material was removed by filtration and the filtrate was evaporated to dryness. The residue which contained mainly one isomer was purified by silica gel column chromatography using 0-2% MeOH in CH_2Cl_2 as the eluent to yield 1.10 g (84.2%) of **10c** as a viscous liquid. UV (MeOH): λ_{max} 288 nm (ϵ 9300); ^1H NMR: δ 1.92 (s, 3 H, COCH_3), 3.77 (t, 2 H, $\text{OCH}_2\text{CH}_2\text{O}$), 4.07 (t, 2 H, $\text{OCH}_2\text{CH}_2\text{O}$), 5.78 (s, 2 H, NCH_2), 9.09 (s, 1 H, C_8H), 9.19 (s, 1 H, C_2H). *Anal.* Calcd. for $\text{C}_{11}\text{H}_{11}\text{N}_5\text{O}_3$: C, 50.57; H, 4.24; N, 26.81. Found: C, 50.67; H, 4.14; N, 26.80.

4-Amino-8-[(2-hydroxyethoxy)methylamino]pyrimido[5,4-*d*]pyrimidine (13d). To a solution of **10c** (0.75 g, 2.87 mmol) in MeOH (20 mL) was added NH_4OH (40 mL) and the mixture was stirred at room temperature for 20 h. The solvents were evaporated and the solid was washed with a small amount of H_2O and MeOH to yield 0.28 g (41%) of **13d**, mp 216-218 °C; UV (MeOH): λ_{max} 292 nm (ϵ 18,600), 304 (16,200), 318 (13,700), 334 (9700); IR: ν 3170, 3320 (OH, NH, NH_2) cm^{-1} ; ^1H NMR: δ 3.49, 3.52 (2s, 4 H, $\text{OCH}_2\text{CH}_2\text{O}$), 4.59 (s, 1 H, OH), 4.99 (d, 2 H, NCH_2), 7.74, 7.95 (2s, 2 H, NH_2), 8.40 (s, 1 H, C_6H), 8.50 (s, 1 H, C_2H), 8.90 (br s, 1 H, NH); MS: m/e 237.3 (M+H). *Anal.* Calcd. for $\text{C}_9\text{H}_{12}\text{N}_6\text{O}_2$: C, 45.75; H, 5.12; N, 35.58. Found: C, 45.37; H, 4.83; N, 35.49.

9-[(1,3-Dibenzyloxy-2-propoxy)methyl]purine-6-carbonitrile (10e). To a solution of **9** (1.0 g, 6.89 mmol) in dry CH_3CN (75 mL) was added NaH (0.28 g, 7 mmol, 60% dispersion in oil). The mixture was stirred at room temperature for 30 min before a solution of 1,3-dibenzyloxy-2-chloromethyl glycerol (prepared from 2.72 g, 10 mmol of 1,3-dibenzyloxy-2-propanol) in CH_3CN (20 mL) was added. The mixture was stirred overnight and the insoluble material was

removed by filtration. The filtrate was evaporated and the residue containing mainly N-9 isomer was purified by silica gel column chromatography using 0-2% MeOH in CH₂Cl₂ as the eluent to yield 2.3 g (77.7%) of **10e** as a viscous oil. UV (MeOH): λ_{max} 290 nm (ϵ 8300); ¹H NMR: δ 3.44 (m, 4 H, 2 OCH₂), 4.12 (m, 1 H, OCH), 4.33, 4.34 (2s, 4 H, 2 CH₂Ph), 5.85 (s, 2 H, CH₂), 7.10-7.33 (m, 10 H, 2 Ph), 9.06 (s, 1 H, C₈H), 9.13 (s, 1 H, C₂H). *Anal.* Calcd. for C₂₄H₂₃N₅O₃: C, 67.12; H, 5.40; N, 16.31. Found: C, 66.96; H, 5.21; N, 15.47.

4-Amino-8-[(1,3-dihydroxy-2-propoxy)methylamino]pyrimido[5,4-d]-pyrimidine (13f). To a solution of **10e** (1 g, 2.33 mmoles) in MeOH (50 mL) was added NH₄OH (50 mL). The mixture was stirred at room temperature for 20 h. The solvents were evaporated to give a solid, which was found to be a complex mixture of compounds by TLC procedures. The desired product **13e** was isolated by silica gel column chromatography using 0-3% MeOH in CH₂Cl₂ as the eluent. To a solution of the pure **13e** (0.2 g) in absolute EtOH (100 mL) were added cyclohexene (20 mL) and Pd(OH)₂ (100 mg, 20% on carbon). The mixture was heated under reflux for 40 h. The reaction mixture was filtered hot through a Celite pad and the pad was washed with hot MeOH (2 \times 30 mL). The combined filtrates were evaporated. The solid thus obtained was dissolved in MeOH and adsorbed onto silica gel. The dried silica gel was loaded on a silica gel column and the product was eluted with 0-12% MeOH in CH₂Cl₂. Yield: 50 mg (8 %); mp 162-164 °C; UV (MeOH): λ_{max} 292 nm (ϵ 14,800), 304 (12,700), 318 (10,500), 336 (7500); IR: ν 3180, 3310 (OH, NH, NH₂) cm⁻¹; ¹H NMR: δ 3.40 (m, 4 H, 2OCH₂), 3.61 (m, 1 H, OCH), 4.58 (t, 2 H, 2 OH), 5.09 (d, 2 H, CH₂), 7.75, 7.96 (2s, 2 H, NH₂), 8.40 (s, 1 H, C₆H), 8.49 (s, 1 H, C₂H), 8.85 (t, 1 H, NH); MS: m/e 267.3 (M+H).

REFERENCES

1. Chu, C. K. and Cutler, S. J., *J. Heterocycl. Chem.*, **23**, 289 (1986).
2. Whitley, R. J., Alford, C. A., Hirsch, M. S., Schooley, R. T., Luby, J. P., Aoki, F. Y., Hanley, D., Nahmias, A., and Soong, S-J., *New Eng. J. Med.*, **314**, 144 (1986).
3. Larson, A., Alenius, S., Johansson, N. -G., and Oberg, B., *Antiviral Res.*, **3**, 77 (1983).
4. Smith, K. O., Galloway, K. S., Kennel, W. L., Ogilvie, K. K., and Radatus, B. K., *Antimicrob. Agents Chemother.*, **22**, 55 (1982).

5. Lewis, A. F., Drach, J. C., Fennewald, S. M., Ptak, R. G., Sommadossi, J-P., Revankar, G. R., and Rando, R. F., *Antimicrob. Agents Chemother.*, **38**, 2889 (1994).
6. Lewis, A. F., Revankar, G. R., Fennewald, S. M., Huffman, J. H., and Rando, R. F., *J. Heterocycl. Chem.*, (In press).
7. Bhattacharya, B. K., Rao, T. S., Lewis, A. F., Revankar, G. R., Sanghvi, Y. S., and Robins, R. K., *J. Heterocycl. Chem.*, **30**, 1341 (1993).
8. Rao, T. S. and Revankar, G. R., *J. Heterocycl. Chem.*, (In press).
9. Ramasamy, K., Ugarkar, B. G., McKernan, P. A., Robins, R. K., and Revankar, G. R., *J. Med. Chem.*, **29**, 2231 (1986).
10. Srivastava, P. C., Revankar, G. R., Robins, R. K., and Rousseau, R. J., *J. Med. Chem.*, **24**, 393 (1981).
11. Westover, J. D., Revankar, G. R., Robins, R. K., Madsen, R. D., Ogden, J. R., North, J. A., Mancuso, R. W., Rousseau, R. J., and Stephan, E. L., *J. Med. Chem.*, **24**, 941 (1981).
12. Robins, R. K., Revankar, G. R., and Sanghvi, Y. S., U. S. Patent 5041542 (August 20, 1991).
13. Sanghvi, Y. S., Larson, S. B., Matsumoto, S. S., Nord, L. D., Smee, D. F., Willis, R. C., Avery, T. L., Robins, R. K., and Revankar, G. R., *J. Med. Chem.*, **32**, 629 (1989).
14. Lovelette, C. A., *J. Heterocycl. Chem.*, **16**, 555 (1979).
15. Berman, H. M., Rousseau, R. J., Mancuso, R. W., Kreishman, G. P., and Robins, R. K., *Tetrahedron Lett.*, 3099 (1973).
16. Robins, R. K., Srivastava, P. C., Revankar, G. R., Novinson, T., and Miller, J. P., *J. Heterocycl. Chem.*, **19**, Suppl. Issue, S93-S103 (1982).
17. Mackay, L. B. and Hitchings, G. H., *J. Am. Chem. Soc.*, **78**, 3511 (1956).
18. Poonian, M. S. and Nowoswiat, E. F., *J. Org. Chem.*, **45**, 203 (1980).
19. Earl, R. A. and Townsend, L. B., *J. Heterocycl. Chem.*, **11**, 1033 (1974).
20. Robins, M. J. and Hatfield, P. W., *Can. J. Chem.*, **60**, 547 (1982).
21. Martin, J. C., Dvorak, C. A., Smee, D. F., Matthews, T. R., and Verheyden, J. P. H., *J. Med. Chem.*, **26**, 759 (1983).
22. Barnard, D. L., Huffman, J. H., Sidwell, R. W., and Reist, E. J., *Antiviral Res.*, **22**, 77 (1993).

Received February 6, 1995

Accepted May 9, 1995